Curosurf (Poractant Alfa) Market Report 2026

Curosurf (Poractant Alfa) Market Overview

• The Curosurf (Poractant Alfa) market growth in the historic period has been driven by high incidence of preterm births, proven efficacy in rds treatment • Market expansion is supported by increasing premature birth rates globally, expansion of nicu infrastructure • Growth Driver: Impact Of Rising Respiratory Disorders On The Growth Of The Pulmonary Surfactant Market • Market Trend: Innovative Inhaled Gene Therapy Advancements In The Curosurf Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Curosurf (Poractant Alfa) Market?

Curosurf (poractant alfa) refers to a synthetic pulmonary surfactant used primarily for the treatment and prevention of respiratory distress syndrome (RDS) in preterm neonates. It is a synthetic version of a natural substance called pulmonary surfactant, which is produced in the lungs to help reduce surface tension and prevent the collapse of the alveoli (small air sacs) in the lungs. The main types of curosurf (poractant alfa) are Natural Poractant Alfa and Synthetic Poractant Alfa. Natural poractant alfa is a surfactant derived from animal lung extract, primarily porcine (pig) sources. It consists of various sales channels, including direct sales, distribution channels, and online marketplaces, for various applications, such as pulmonary edema, respiratory distress syndrome, and other respiratory disorders. End users include hospitals, clinics, and ambulance services.

What Is The Curosurf (Poractant Alfa) Market Growth Forecast?

The growth in the forecast period can be attributed to increasing premature birth rates globally, expansion of nicu infrastructure, improved neonatal care access, rising awareness of early rds intervention, continued clinical validation. Major trends in the forecast period include rising use in neonatal intensive care, growing adoption of synthetic surfactants, increasing focus on preterm birth management, standardization of rds treatment protocols, expansion of hospital based neonatal therapies.

What Are The Drivers Of The Curosurf (Poractant Alfa) Market?

Increasing prevalence of respiratory disorders is expected to propel growth of the curosurf (poractant alfa) market going forward. Respiratory disorders refer to common conditions that affect the lungs and breathing, such as asthma, COPD, and lung cancer, leading to difficulty in breathing and reduced lung function. The prevalence of respiratory disorders is increasing due to rising air pollution, which exacerbates conditions such as asthma, and the aging population, which contributes to a higher incidence of age-related diseases such as COPD. Poractant alfa is used to treat neonatal respiratory distress syndrome by improving lung function and facilitating breathing in premature infants through administration via an endotracheal tube. For instance, in December 2023, according to the National Library of Medicine, a US-based medical library, the global number of chronic obstructive pulmonary disease (COPD) cases among those 25 and older is projected to rise by 23% by 2050, reaching nearly 600 million. Therefore, the increasing prevalence of respiratory disorders is driving the growth of the curosurf (poractant alfa) industry. The growing prevalence of premature births is expected to propel the growth of the Curosurf (poractant alfa) market going forward. Premature births refer to babies born before 37 weeks of gestation, as a full-term pregnancy typically lasts about 40 weeks. The rise in premature births is linked to older maternal age and the increased use of assisted reproductive technologies, which often lead to multiple pregnancies. Poractant alfa is used to treat premature infants with respiratory distress syndrome by reducing lung surface tension, helping the lungs stay open, and improving oxygen exchange. For instance, in July 2025, according to the Office for National Statistics, a UK-based government department, reported that in 2024, England and Wales recorded 594,677 live births, marking a rise of 3,605 (0.6%) from the 591,072 births reported in 2023. Therefore, growing prevalence of premature births is driving the growth of Curosurf (poractant alfa) industry.

Key Players In The Global Curosurf (Poractant Alfa) Market

Major companies operating in the curosurf (poractant alfa) market are Chiesi Farmaceutici S.p.A

Global Curosurf (Poractant Alfa) Market Trends and Insights

Major companies operating in the curosurf (poractant alfa) market are focusing on developing innovative solutions, such as novel inhaled gene therapy to address unmet needs in respiratory disorders. Novel inhaled gene therapy refers to a cutting-edge approach where therapeutic genes are delivered directly to the lungs via inhalation, typically through aerosolized particles or nanoparticles. For instance, in November 2024, AlveoGene, a UK-based developer of gene therapy, received Rare Pediatric Disease Designation (RPDD) from the FDA for AVG-002, a novel inhaled gene therapy targeting lethal neonatal surfactant protein B (SP-B) deficiency, a severe genetic disorder that leads to respiratory failure in infants. SP-B deficiency, caused by mutations in the SFTPB gene, currently has limited treatment options, primarily relying on lung transplantation. AVG-002 utilizes AlveoGene's InGenuity platform to deliver a functional SP-B gene directly to the lungs, showing promising results in preclinical studies.

What Defines the Curosurf (Poractant Alfa) Market?

The curosurf (poractant alfa) market consists of sales of generic versions of poractant alfa, fostair, flemax, bricanils, and synthetic pulmonary surfactants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Curosurf (Poractant Alfa) Market Report 2026?

The curosurf (poractant alfa) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the curosurf (poractant alfa) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.